Compare Citigroup Inc. (C) vs Mesoblast Limited (MESO) Price & Performance

Citigroup Inc.Trade

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Citigroup Inc. vs Mesoblast Limited — how do they compare? Citigroup Inc. trades at $134.35 (market cap $227.30B), while Mesoblast Limited trades at $17.69 (market cap $2.12B). The key difference: Citigroup Inc. is far larger — about 107.2× Mesoblast Limited's market cap, and Citigroup Inc. pays a 1.8% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

	C	MESO
Market Cap	$227.30B	$2.12B
Sector	Financials	Technology
52-Week High	$145.67	$20.96
52-Week Low	$90.02	$10.96
Dividend Yield	1.8%	—
Enterprise Value	—	$2.13B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citigroup Inc.

Citigroup (C) trades at $140.70, up 0.07% on the day, with a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to $85.21B in 2025, with net income margin improving to 16.78%. The stock is supported by positive analyst sentiment, with 59% recommending Buy and a consensus price target of $157.25. Recent news highlights robust trading and investment banking performance driving the best quarterly results in a decade.

The outlook remains positive given earnings momentum and strategic investments, but risks include volatile cash flows from operations and high leverage. Upside potential exists if the company sustains revenue growth and improves operational efficiency, though macroeconomic sensitivity and competitive pressures could limit gains.

Mesoblast Limited

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

Citigroup beats Q2 earnings estimates with $24.77B revenue and $3.15 EPS, driven by strong trading and banking.Tony Dante · 15 hours agoBullish Citigroup posts strong Q2 with 14% revenue growth, 61% EPS jump, and boosts dividends by 12%.Seeking Alpha · 19 hours agoBullish Citigroup beats Q2 revenue estimates on strong trading and investment banking resultsProactive Investors · 1 day agoBullish View details →

MESO

Mesoblast completes treatment of 300 patients in Phase 3 trial for chronic low back pain therapy.GlobeNewsWire · 1 day agoBullish Mesoblast advances to commercial stage with FDA-approved Ryoncil and strong early revenue growth.Seeking Alpha · 4 days agoBullish View details →

About Citigroup Inc.

Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.